JP2023527025A5 - - Google Patents

Info

Publication number
JP2023527025A5
JP2023527025A5 JP2022572622A JP2022572622A JP2023527025A5 JP 2023527025 A5 JP2023527025 A5 JP 2023527025A5 JP 2022572622 A JP2022572622 A JP 2022572622A JP 2022572622 A JP2022572622 A JP 2022572622A JP 2023527025 A5 JP2023527025 A5 JP 2023527025A5
Authority
JP
Japan
Prior art keywords
disease
cancer
carboxamide
trifluoromethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022572622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527025A (ja
Filing date
Publication date
Priority claimed from GBGB2008051.1A external-priority patent/GB202008051D0/en
Priority claimed from GBGB2016709.4A external-priority patent/GB202016709D0/en
Application filed filed Critical
Priority claimed from PCT/EP2021/064166 external-priority patent/WO2021239863A1/en
Publication of JP2023527025A publication Critical patent/JP2023527025A/ja
Publication of JP2023527025A5 publication Critical patent/JP2023527025A5/ja
Pending legal-status Critical Current

Links

JP2022572622A 2020-05-28 2021-05-27 ミトコンドリア機能不全の治療のためのusp30阻害剤としてのn-(1-シアノ-ピロリジン-3-イル)-5-(3-(トリフルオロメチル)フェニル)オキサゾール-2-カルボキサミド誘導体及び対応するオキサジアゾール誘導体 Pending JP2023527025A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2008051.1A GB202008051D0 (en) 2020-05-28 2020-05-28 Novel compounds
GB2008051.1 2020-05-28
GBGB2016709.4A GB202016709D0 (en) 2020-10-21 2020-10-21 Novel compounds
GB2016709.4 2020-10-21
PCT/EP2021/064166 WO2021239863A1 (en) 2020-05-28 2021-05-27 N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction

Publications (2)

Publication Number Publication Date
JP2023527025A JP2023527025A (ja) 2023-06-26
JP2023527025A5 true JP2023527025A5 (https=) 2024-06-03

Family

ID=76444366

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572622A Pending JP2023527025A (ja) 2020-05-28 2021-05-27 ミトコンドリア機能不全の治療のためのusp30阻害剤としてのn-(1-シアノ-ピロリジン-3-イル)-5-(3-(トリフルオロメチル)フェニル)オキサゾール-2-カルボキサミド誘導体及び対応するオキサジアゾール誘導体

Country Status (12)

Country Link
US (1) US20230219939A1 (https=)
EP (1) EP4157834B1 (https=)
JP (1) JP2023527025A (https=)
KR (1) KR20230016674A (https=)
CN (1) CN115667252A (https=)
AU (1) AU2021279199A1 (https=)
BR (1) BR112022020644A2 (https=)
CA (1) CA3185027A1 (https=)
CO (1) CO2022014135A2 (https=)
IL (1) IL298526A (https=)
MX (1) MX2022014429A (https=)
WO (1) WO2021239863A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640556B (zh) * 2012-09-17 2019-08-06 霍夫曼-拉罗奇有限公司 Usp30抑制剂及其使用方法
GB201912674D0 (en) * 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
JP2024544660A (ja) 2021-12-01 2024-12-03 ミッション セラピューティクス リミティド Usp30阻害剤としての活性を有する置換n-シアノピロリジン
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
EP1272467A4 (en) 2000-04-06 2003-05-07 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
SG174050A1 (en) 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
US20090264431A1 (en) 2007-08-20 2009-10-22 Palovich Michael R Novel cathepsin c inhibitors and their use
WO2009129371A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
WO2009129365A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
RS58361B1 (sr) 2013-07-31 2019-03-29 Merck Patent Gmbh Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba
US9963444B2 (en) 2014-05-19 2018-05-08 Northeastern University N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof
US20170095457A1 (en) 2014-05-27 2017-04-06 David Lonergan Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
CA2976741C (en) * 2015-03-30 2023-01-17 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
CN108884068B (zh) 2016-03-24 2021-02-26 特殊治疗有限公司 作为dub抑制剂的1-氰基-吡咯烷衍生物
US11014912B2 (en) 2016-09-27 2021-05-25 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
US10968172B2 (en) 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
GB2563595B (en) 2017-06-19 2020-04-15 Edwards Ltd Twin-shaft pumps
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
GB2571731A (en) 2018-03-06 2019-09-11 Mission Therapeutics Ltd Novel compounds and uses
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的ペプチダーゼ30(usp30)阻害剤として有用な縮合二環化合物
US11572374B2 (en) 2018-08-14 2023-02-07 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
JP7530889B2 (ja) 2018-10-05 2024-08-08 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ30(usp30)阻害剤として作用する縮合ピロリン
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds

Similar Documents

Publication Publication Date Title
JP2023527025A5 (https=)
JP2022546717A5 (https=)
JP2023520727A5 (https=)
JP2020521730A5 (https=)
JP2019504009A5 (https=)
JP2023528087A5 (https=)
JP2019501142A5 (https=)
JP2019533659A5 (https=)
JP2019503362A5 (https=)
JP2019513135A5 (https=)
JP2023529570A5 (https=)
AP813A (en) Urea derivatives as inhibitors of IMPDH enzyme.
JP2018524367A5 (https=)
HRP20250891T1 (hr) 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primjenu u liječenju mitohondrijske disfunkcije, raka i fibroze
JP2020524166A5 (https=)
JP2019532938A5 (https=)
JP2016512844A5 (https=)
JP2023518948A5 (https=)
JP2019508467A5 (https=)
JP2024523623A5 (https=)
EP2699557B1 (en) 3-(oxazol-2-yl-ethoxy)- and 3-(thiazol-2-yl-ethoxy)-benzamide derivatives as anti-bacterial agents
FI4363406T3 (fi) Nlrp3-inflammasomin estäjiä
JP2020512298A5 (https=)
WO2010115836A4 (en) Substituted piperidines as ccr3 antagonists
RU2019111882A (ru) Антагонисты trpv4